📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
518 analysed today
FollowTelegram
518
Today
149,919
All-time analysed
42,971
Positive
6,669
Negative
91,572
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
Zim Laboratories to Raise ₹35 Crore via Preferential Issue to Florintree Trinex LLP
Zim Laboratories Limited has called for an Extraordinary General Meeting (EGM) on February 16, 2026, to approve a preferential equity issuance. The company intends to raise approximately ₹35 crore by issuing 47,64,497 equity shares to Florintree Trinex LLP, a non-promoter investor. The shares are priced at ₹73.46 each, which includes a premium of ₹63.46 per share. This capital infusion is expected to strengthen the company's balance sheet and fund future growth requirements.
Key Highlights
Issuance of up to 47,64,497 equity shares at a price of ₹73.46 per share
Total fundraise amount capped at approximately ₹34,99,99,950 (₹35 crore)
The entire issue is allocated to Florintree Trinex LLP, a non-promoter entity
Relevant date for floor price determination was set as January 16, 2026
EGM to be held on February 16, 2026, with remote e-voting starting February 13
👀 What to Watch
Investors should view this as a positive development as it brings in institutional capital, though they should account for the resulting equity dilution. Monitor the company's subsequent disclosures regarding the specific utilization of these funds for expansion or debt reduction.
Zim Laboratories to Raise ₹35 Crore via Preferential Issue to Florintree Trinex LLP
The Board of Zim Laboratories has approved a preferential issue of 47,64,497 equity shares to Florintree Trinex LLP at a price of ₹73.46 per share. This transaction aims to raise approximately ₹35 crore in cash consideration from a non-promoter investor. Post-allotment, Florintree Trinex LLP will hold an 8.91% stake in the company. An Extra-ordinary General Meeting (EGM) is scheduled for February 16, 2026, to obtain shareholder approval for this issuance.
Key Highlights
Issuance of up to 47,64,497 equity shares at a fixed price of ₹73.46 per share
Total fundraise amount aggregates to approximately ₹34,99,99,950
Florintree Trinex LLP to emerge as a significant non-promoter shareholder with an 8.91% stake
Extra-ordinary General Meeting (EGM) convened for February 16, 2026, for shareholder voting
The capital infusion is intended to support the company's growth and financial requirements
👀 What to Watch
Investors should view this as a positive development as it brings in growth capital and a professional investor. Monitor the EGM outcome and subsequent updates on how the management intends to deploy this capital for expansion.
Zim Laboratories to Raise ₹35 Crore via Preferential Issue to Florintree Trinex LLP
Zim Laboratories has approved a preferential issue of 47,64,497 equity shares to Florintree Trinex LLP, a non-promoter entity. The shares are priced at ₹73.46 each, resulting in a total capital infusion of approximately ₹35 crore. Post-allotment, the investor will hold an 8.91% stake in the company. The proposal is subject to shareholder approval at an Extra-ordinary General Meeting (EGM) scheduled for February 16, 2026.
Key Highlights
Issuance of up to 47,64,497 equity shares at a price of ₹73.46 per share.
Total fundraise aggregates to approximately ₹34.99 crore.
Investor Florintree Trinex LLP to hold an 8.91% stake post-issue.
Extra-ordinary General Meeting (EGM) for shareholder approval set for February 16, 2026.
The fundraise is conducted on a private placement basis to a non-promoter group.
👀 What to Watch
Investors should monitor the company's plans for utilizing this capital and note the ~9% equity dilution. The entry of a professional investment entity like Florintree is typically a positive signal for mid-cap pharma companies.
Zim Laboratories Receives CDSCO Approval for Naproxen + Esomeprazole FDC Capsules
Zim Laboratories has secured approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market a novel Fixed Dose Combination (FDC) of Naproxen and Esomeprazole. The product utilizes the company's proprietary drug delivery technology, combining delayed-release minitablets and pellets in a single capsule. A commercial supply agreement is already in place with an Indian pharmaceutical company for this product. The company expects a commercial launch in India by FY 2026-27, strengthening its position in the pain management and gastro-protective segments.
Key Highlights
Received CDSCO approval for Naproxen Delayed Release (375mg/500mg) and Esomeprazole (20mg) FDC capsules.
Product developed using proprietary drug delivery systems including minitablets and pellets.
Commercial supply agreement already signed with a domestic pharmaceutical partner.
Targeting commercial launch in the Indian market during FY 2026-27.
Indicated for symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
👀 What to Watch
Investors should view this as a positive validation of ZIMLAB's R&D capabilities and New Innovative Product (NIP) pipeline. Monitor the execution of the supply agreement and the subsequent revenue impact starting FY27.
